OBJECTIVE: The aim of this study was to determine the effectiveness and @entity137 of monthly treatment with intravenous @entity1311 for @entity1 with advanced or recurrent uterine @entity1377 (UPSC). METHODS: Consenting @entity1 with histologically confirmed advanced (FIGO stage III or IV) or recurrent UPSC were treated on an Institutional Review Board approved protocol of a 24-h intravenous infusion of 200 mg/m(2) of @entity1311 every 3 weeks. Both measurable and nonmeasurable disease cases were enrolled. Treatment was continued until disease progression, @entity1 intolerance, or (in @entity1 with nonmeasurable disease) completion of six courses. RESULTS: Twenty @entity1 received from 1 to 11 cycles of therapy. Two @entity1 died of disease after 1 cycle of therapy and were not evaluable for response. Among 13 @entity1 with measurable @entity5 receiving 2 or more cycles of therapy, 4 had a complete clinical response and 6 had a partial response (objective response rate, 77%). The median time to progression was 7.3 months (range, 2-21 months). All 3 remaining @entity1 with measurable disease had stable disease for a median of 6 months. The 5 @entity1 without evaluable disease received 5 to 6 cycles of adjuvant @entity1311 . Three developed recurrence (range, 4-10 months; median, 7.2 months). @entity1398 was the major @entity137 . Eleven of the 20 @entity1 required @entity1261 support, and 9 were hospitalized for @entity221 . One @entity1 had reversible @entity299 , which might have been related to @entity1311 treatment. At the time of analysis (mean follow-up, 23 months; range, 4.3-59.9 months), 13 @entity1 had died of disease, 4 were alive with disease, and 2 were disease free. All 3 disease-free @entity1 had been treated for nonmeasurable advanced stage disease. CONCLUSION: @entity1311 appears to have excellent activity in the treatment of advanced or recurrent UPSC, an uncommon but aggressive @entity5 . Longer survival appears to be more common among @entity1 with @entity66 .

Treatment of uterine XXXX with @entity1311 .

@entity1 :: ('9606', 'Species') :: ['women', 'patients', 'woman', 'patient'] @entity1377 :: ('MESH:D002291', 'Disease') :: ['papillary serous carcinoma'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity1261 :: ('1440', 'Gene') :: ['G-CSF'] @entity66 :: ('MESH:D004194', 'Disease') :: ['small-volume disease'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'malignancy'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel', 'Paclitaxel'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['Neutropenia'] @entity299 :: ('MESH:D006331', 'Disease') :: ['cardiac symptoms'] @entity221 :: ('MESH:D005334', 'Disease') :: ['neutropenic fever']
@entity1377 :: (MESH:D002291,Disease) :: ['papillary serous carcinoma']
